The Chemours (NYSE:CC) issued its earnings results on Sunday. The specialty chemicals company reported $0.71 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.08, MarketWatch Earnings reports. The business had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.40 billion. The Chemours had a negative net margin of 2.35% and a positive return on equity of 46.27%. The Chemours’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the business posted $0.71 EPS.
Shares of CC traded up $0.28 during midday trading on Tuesday, hitting $31.29. The company’s stock had a trading volume of 19,524 shares, compared to its average volume of 1,456,575. The company has a quick ratio of 1.23, a current ratio of 1.99 and a debt-to-equity ratio of 5.54. The Chemours has a one year low of $10.29 and a one year high of $32.21. The stock has a market capitalization of $5.17 billion, a price-to-earnings ratio of -43.07 and a beta of 2.30. The company’s fifty day simple moving average is $28.53 and its two-hundred day simple moving average is $26.06.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 15th. Shareholders of record on Monday, May 17th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, May 14th. This represents a $1.00 annualized dividend and a yield of 3.20%. The Chemours’s dividend payout ratio is currently 39.84%.
About The Chemours
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications.
Receive News & Ratings for The Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Chemours and related companies with MarketBeat.com's FREE daily email newsletter.